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PRECISION MEDICINE
Precision Medicine and Type 2 Diabetes Mellitus
Abstract
This literature review was carried out based on the completed of an Objective Structured
Clinical Examination (OSCE) and oral defense. After reviewing the case report, the topic of

precision medicine and the treatment of type II diabetes was selected. Using CINAHL Complete
and PubMed, a search was conducted using the controlled vocabulary terms precision medicine,
pharmacogenetics, genetically guided therapy, type II diabetes, and diabetes mellitus type II. The
search terms were connected using the Boolean connectors AND and OR. The search was further
refined using the following criteria: published between 1/1/2015 and 12/31/2020, English
language, peer-reviewed, and human. Guidelines from the American Association of Clinical
Endocrinologists and the American Diabetes Association were reviewed for current
recommendations on second-line treatment recommendations for type II diabetes.
The literature review shows precision medicine for the treatment of type II diabetes has
started with monogenic diabetes and neonatal diabetes as well as specific genetic markers that
may indicate patient response to second-line medications. The most impactful advancement of
type II diabetes management through precision medicine is the sub stratification of diabetes into
five subgroups and their associated genetic makeup and risk of complications. It also outlines
that precision medicine also includes lifestyle intervention as well as machine learning. Further
research is needed before implementation within healthcare regarding genomic markers, cost
feasibility, and transferability across healthcare organizations.
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Background
For many years there have been type I and type II diabetes. Over time, this has evolved to
include gestational diabetes, latent autoimmune diabetes in adults, neonatal diabetes, and
maturity-onset diabetes of youth. Of these, type 2 diabetes is the most common (American
Diabetes Association, 2015). According to the American Diabetes Association (2018), in 2015,
more than 30.3 million Americans were living with diabetes and of those, only 23.1 million were
diagnosed. Currently, diabetes remains the seventh leading cause of death in the United States.
However, it is widely accepted that these deaths are underreported as only 35 to 40% of people
with diabetes who died had diabetes listed on their death certificate (American Diabetes
Association, 2018). It is no surprise that with the rising incidence of type II diabetes, the cost of
diabetes continues to rise as well. Recent statistics show that in 2017, type II diabetes cost the
United States $327 billion due to both direct and indirect costs (American Diabetes Association,
2018). Compared to individuals living without diabetes, patients with diabetes have higher rates
of all infections, including bone and joint infections, sepsis, and cellulitis (Carey et al., 2018).
The risk of cellulitis for individuals living with type II diabetes increases with neuropathy, which
is the loss of sensation, particularly in the hands and feet. Hyperglycemia also increases the risk
of infections by providing infectious microorganisms nutrients to grow and thrive.
Organizations such as the American Diabetes Association (2019) and the American
Association of Clinical Endocrinologists (2020) have created treatment algorithms that all agree
first-line treatment, behind nutrition and lifestyle modification, should begin with metformin up
to 2000 mg per day. In the case study outlined below, the individual was being treated with
metformin at 1000 mg daily. However, her glucose remains elevated. Due to sustained
hyperglycemia, it is recommended to increase metformin to the optimal dose of 2000 mg per day
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as agreed upon by the American Diabetes Association (2019) and the American Association of
Clinical Endocrinologists (2020). However, after the first-line treatment with metformin, the
optimal second-line treatment becomes less clear. Options to select from include sulfonylureas,
thiazolidinediones, ⍺-glucosidase inhibitors, dipeptidyl peptidase-4 (DPP-4) inhibitors,
glucagon-like peptide-1 (GLP-1) analogs, SGLT2 inhibitors. A combination of these is often
utilized before progressing to one or more of the various types of rapid, short, intermediate, and
long-acting insulins.
In 2015, during the State of the Union Address, President Obama announced a Precision
Medicine Initiative aimed at patient-powered research. This initiative was implemented to
accelerate biomedical discoveries to help clinicians better select treatments that will work best
for their patients (The White House, Office of the Press Secretary, 2015). With the
implementation of precision medicine in the treatment of type II diabetes, the increased
achievement of optimal glycemic control could reduce the risk of complications, including
cellulitis and improve the diabetes outcomes.
In this literature review, a case report will be incorporated describing a woman in her late
50s who presented to the clinic with fever, chills, confusion, and forgetfulness for the past one
day. She has a history of hypertension, dyslipidemia, as well as type 2 diabetes. Despite being on
metformin, her glucose remained elevated. Hyperglycemia, as a result, was likely a contributing
factor to her sepsis. Sepsis was identified to have resulted from cellulitis in her left lower
extremity. The main emphasis of this literature review will be looking at the evidence-based
recommendations utilizing precision medicine in the treatment of type II diabetes to help
determine which secondary line of medication is optimal for individual patients with type II
diabetes.
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Case report
Chief Complaint: 58-year-old female who was brought to the clinic today by her sister with
complaints of fever, chills, confusion, and forgetfulness for one day
HPI: Jessica Brown is a pleasant 58-year-old female who presents the clinic today brought in by
her sister due to symptoms of fever, chills, confusion, and forgetfulness for the past day. She
denies any recent exposure to illness. She denies any upper respiratory symptoms, including
coughing, congestion, runny nose, sinus pressure, wheezing, or shortness of breath. Change and
eyes any urinary symptoms, including urgency, frequency, or pain with urination. Her health
history is positive for diabetes, hypertension, and dyslipidemia. She does not self-monitor
glucose at home. She reports taking ibuprofen within the last two hours. Fever today in the clinic
at 104.7°F. She denies any recent hospitalization or antibiotic use. She denies any chest pain
shortness of breath palpitations dyspnea on exertion or lower extremity edema. She is not able to
identify any aggravating factors. She denies any new rashes lesions or cuts on her skin. Her
symptoms have progressively worsened over the past day. She states only presenting to the clinic
today due to her sister's concerns regarding her confusion and forgetfulness. Her confusion and
forgetfulness make her a poor historian.
Past Medical History
Medical:
1. Dyslipidemia
2. Hypertension
3. Type 2 diabetes mellitus
Surgical:
1. Tubal ligation
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Medications:
1. Ezetimibe (ZETIA) 5 mg tablet
2. Lopressor 50 mg two times daily
3. Lisinopril 10 mg daily
4. Metformin 1000 mg daily
5. Fish oil 1000 mg daily
6. Zocor 80 mg daily
7. Aspirin 325mg daily
Allergies: No known allergies
Screening: Mammogram, colonoscopy, and pap smear up to date. All negative on most recent
exams.
Immunizations: Up to date on all immunizations including influenza and pneumonia
Social History: She is retired and enjoys reading and watching television in her free time. She
quit smoking in 2002. She denies any medical or recreational drug use or alcohol consumption.
She exercises one to two times per week.
Family History: This is a positive history only for cardiovascular disease and type II diabetes in
her father.
Review of Systems
General: Positive for fevers, chills, confusion, and forgetfulness. She denies weight loss, fatigue,
or changes in sleep.
HEENT: Denies headache, hearing change, vision change, vertigo, congestion, rhinorrhea, or
sore throat
Cardiovascular: Denies chest pain, palpitations, and edema. No history of heart murmurs
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Respiratory: Denies cough, dyspnea, wheezing, or pain
Musculoskeletal: Denies muscle or joint pain/stiffness, back pain, or swelling of joints
Urinary: Denies urgency, frequency, pain, burning or hematuria
Gastrointestinal: Denies vomiting, diarrhea, constipation or appetite change
Skin: Denies rashes, itching, dryness or color change
Neurologic: Denies headaches, syncope, seizures, or difficulty with balance or coordination.
Positive for numbness and tingling in bilateral toes and confusion.
Physical Examination
General: Healthy appearing, alert, oriented x3, well dressed, good hygiene, no acute distress.
Poor historian.
Vitals: BP: 194/83, HR: 119, RR: 14, Temp: 104.7 F, O2: 93% RA, weight: 260 lb, height 5’5”
HEENT: Atraumatic, PERRL, EOMs intact, external ears normal, ear canals normal, tympanic
membranes normal, no tenderness or discharge, normal lips, tongue, buccal mucosa and pharynx
without lesions, mucus membranes moist, nares patent.
Neck: Full range of motion, supple, no palpable nodes, thyroid within normal limits
Respirations: Normal respirations, good expansion with good diaphragmatic excursion, clear to
auscultation without wheezes or rhonchi.
Cardiovascular: Regular rhythm and rate, S1 and S2 normal; no murmurs. No peripheral
edema.
Abdominal: Soft, non-distended, non-tender, normal bowel sounds in all quadrants, no masses
Musculoskeletal: Full range of motion to all extremities, strength, and sensation intact, capillary
refill <2 seconds.
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Skin: Area of erythema, edema, warmth, and pain with an indefinite border on the anterior
aspect of the left lower limb. Negative for crepitus, vesicles, blisters, or necrosis. No apparent
trauma.
Neurological: Cranial nerves II to XII intact, reflexes symmetric, sensation and gait normal
Differential diagnosis: cellulitis, deep vein thrombosis, contact dermatitis, thrombophlebitis,
stasis dermatitis, hyperglycemia, hypertension, pneumonia, influenza, urinary tract infection,
stroke, alcohol or drug ingestion, dehydration, hyperthermia, carbon monoxide poisoning,
hypoxia
Labs/Imaging
1. CBC with differential – white blood count (12.5) and Seg Neut Absolute (10.1) elevated.
All other counts within normal limits.
2. C-reactive protein – elevated (144.4 mg/dl)
3. CMP – glucose (266 mg/dl) and anion gap with K (22 meq/L) elevated, sodium (132
meq/L), chloride (94 meq/L), CO2 (20 meq/L) below normal limits. All other counts
within normal limits
4. Lactic acid – elevated (4.4 mmol/L)
5. Erythrocyte sedimentation rate – elevated (57 mm/Hr)
Conclusion:
1. Sepsis due to cellulitis of the left lower leg
2. Systolic hypertension
3. Hyperglycemia
Recommendations:
1. Refer the patient to the emergency room for further evaluation and treatment
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2. Follow up in the clinic within one week after hospital discharge
3. Continue to monitor hypertension
4. Consider increasing metformin and the addition of a second line antihyperglycemic
medication
Plan
Send the patient to the emergency room for admission and treatment of sepsis due to
cellulitis. Intravenous antibiotic therapy should be initiated within one hour of presentation after
obtaining cultures. Empiric broad-spectrum antibiotics, such as carbapenem or piperacillintazobactam, should be selected to cover all likely pathogens, including gram-positive and gramnegative bacteria. Intravenous fluids should be initiated within the first three hours to treat and or
prevent intravascular hypovolemia (Schmidt & Mandel, 2020). Follow up recommended within
one week after hospitalization to evaluate hypertension as well as hyperglycemia.
Literature Review
In 2015, during the State of The Union Address, President Barack Obama announced the
Precision Medicine Initiative with the hopes of fast-tracking biomedical discoveries and aiding
clinicians in best-selecting treatments that would be optimal for their patients (The White House,
Office of the Press Secretary, 2015). In modern medicine, a majority of precision medicine
research has been geared toward cancer therapies and treatments. The Precision Medicine
Initiative was aimed not only at cancer research and treatment but also genetic registries that can
be used to further research and medicine for many acute and chronic medical conditions. To
date, there has been little research on precision medicine and type 2 diabetes prevention and
treatment. This literature review will focus on the utilization of precision medication to treat type
2 diabetes. The report will including how monogenic diabetes and neonatal diabetes have paved
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the way for precision medicine, how precision medicine has allowed us to further stratify
diabetes into subgroups, individual responses to specific medications, and the various type of
precision medicine.
Monogenic Diabetes and Neonatal Diabetes
In the early phases of precision medicine and diabetes management, monogenic diabetes,
as well as neonatal diabetes, have led the charge in the utilization of precision medicine in the
management of diabetes. According to Gloyn and Drucker, up to 3% of diabetes cases diagnosed
in children have a monogenic basis (2018). These patients typically present with a diabetes
diagnosis under the age of 25 years old, a strong family history of diabetes, are thin, and have
negative autoantibodies (Gylon & Drucker, 2018). They do, however, have positive C-peptide, a
measure of their insulin production (Gylon & Drucker, 2018). They also typically have a
mutation in the transcription gene HNF1A (Gylon & Drucker, 2018). Frequently these
individuals are misdiagnosed as having type I diabetes. However, instead of requiring multiple
daily insulin injections, many of these patients are sensitive to treatment with sulfonylureas
(Gylon & Drucker, 2018). Through the use of precision medicine, genetic markers have been
identified for individuals diagnosed with monogenic diabetes and recommend the best treatment
options to provide the highest quality of life.
Along with monogenic diabetes, neonatal diabetes has also paved the way for precision
medicine and diabetes management. Neonatal diabetes is diagnosed during the first six months of
life. It has been shown to have mutations at several genes, including KCJN11, SUR1, GCK, and
INS (Prasad & Groop, 2018). Neonatal diabetes can be either transient or permanent and optimal
treatment is dependent on an appropriate genetic diagnosis (Prasad & Groop, 2018). Some forms
of neonatal diabetes not only affect insulin production but can also cause developmental defects.
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Similar to monogenic diabetes, individuals with neonatal diabetes can be sensitive to
sulfonylureas and are often misdiagnosed as having type I diabetes (Prasad & Groop, 2018). In
the clinical application of precision medicine and genetics, it remains limited to the rare genetic
forms of diabetes, including monogenic diabetes and neonatal diabetes (Fitipaldi, McCarthy,
Florez & Franks, 2018).
Stratification into Subgroups
As discussed earlier in this paper, to date, precision medicine has been focused on cancer
research and treatment. It has allowed us to identify the increased risk of cancer, for example, in
those with Ashkenazi Jewish heritage. It has also been recently identified as a common mutation
in the Greenlandic Inuit of the TBC1D4 gene substantially increased the risk of type II diabetes
(Manousaki et al., 2016). Manousaki et al. identify that this gene mutation is present in
approximately 27% of Canadian and Alaskan Inuit (2018). The TBC1D4 gene mutation leads to
increased postprandial glucose values and lower fasting glucose values and, as a result, in
increased risk underdiagnosed this diabetes (Manousaki et al., 2016). Through the utilization of
precision medicine, it would be recommended that those of Greenlandic Inuit heritage should
undergo an oral glucose tolerance test to further assess for type II diabetes (Manousaki et al.,
2016).
In modern medicine, type II diabetes is a diagnosis of exclusion. Hyperglycemia, in the
absence of neonatal diabetes or monogenic diabetes, autoantibodies, trauma, illness, or
medications, is given the diagnosis of type II diabetes (Prastad & Groop, 2018). However, with
precision medicine, using the variable agents of diagnosis including body mass index,
hemoglobin A1c, GAD autoantibodies, C-peptide, and glucose, diabetes is further stratified into
five distinct subgroups (Fitipaldi et al., 2018; Prastad & Groop, 2018; Gloyn & Drucker, 2018).
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1. Severe autoimmune diabetes with the presence of GAD autoantibodies, low insulin
secretion, and poor metabolic control
2. Severe insulin-deficient diabetes with the presence of low insulin secretion, poor
metabolic control and increased risk of retinopathy
3. Severe insulin-resistant diabetes with the presence of severe insulin resistance, obesity,
late-onset, and increased risk of nephropathy
4. Mild obesity-related diabetes with the presence of obesity, early-onset and good
metabolic control
5. Mild age-related diabetes with the presence of late-onset and good metabolic control
Similar to the sub stratification identified above, Dennis et al. similarly defines three subgroups
based on clinical cut offs for obesity and high triglycerides (2018).
1. Group A – Nonobese and normal triglycerides
2. Group B – Nonobese or normal triglycerides
3. Group C – Obese and high triglycerides
These sub stratifications identified through new precision medicine allow providers and
clinicians to begin to look at diabetes as more than type one and type II. By identifying the group
that each patient falls into, the provider will better be able to recommend treatment options for
improved management and quality of life.
Responses to specific medications
After the initiation of dietary and lifestyle changes, the most common treatment for type
II diabetes is the addition of an oral hypoglycemic agent or a non-insulin in an injectable
(Dawed, Zhou & Pearson, 2016). The classes of hypoglycemic agents to treat type II diabetes
include biguanides, sulfonylureas (Sus), meglitinides (glinides), thiazolidinediones (TZDs),
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alpha-glucosidase inhibitors, glucagon-like peptide (GLP)-1 receptors, dipeptidyl peptidase
(DPP)-4 inhibitors, and sodium-glucose transporter (SGLT)-2 inhibitors. Increasing research is
being done around each of these classes of medications and the specific biomarkers that may
enhance or reduce their efficacy for individual patients.
Biguanides include the medication metformin, which is the first-line treatment for
virtually all individuals with new-onset type II diabetes. The mechanism of action for metformin
is the suppression of hepatic glucose production through gluconeogenesis. However, the exact
mechanism of action is still unknown (Yang, Heredia, Beltramo & Soria, 2016). Despite being
the first-line medication, many individuals treated with metformin are considered to have an
inadequate response frequently due to gastrointestinal side effects (Mannino, Andreozzi & Sesti,
(2018). It has been shown, nonetheless, that genetic factors can influence an individual's glucose
response to metformin, including the organic cation transporter (OCT) family, ATM, and SLC
282 (Mannino, Andreozzi & Sesti, (2018). Those individuals with the OCT variant have been
shown to have increased area under the curve compared to those without after metformin
treatment as well as a more significant A1 C reduction during the initiation and maintenance
(Dawed et al., 2016).
If metformin as a first-line medication is not sufficient to bring glucose values within the
target range, a second-line medication must be selected. Through the utilization of precision
medicine, we would anticipate being able to select a second line medication based on the
patient's biomarkers to improve overall treatment, compliance, prevention of complications and
quality-of-life. Markers of high insulin resistance and triglycerides were associated with a
decreased response to DPP-4 inhibitors ( Dennis et al., 2018). However, this response was not
associated with GLP-1 receptor agonists ( Dennis et al., 2018). SGLT-2 inhibitors, despite
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showing promise for those individuals with established ASCVD, heart failure, or CKD the are
relatively new, and evaluation of efficacy and safety of these medications has not yet fully been
established (Heo & Choi, 2019). Each of the second line medications contains a different
mechanism of action aimed at the improvement of glycemic control and has various gene
associations that impact the efficacy for the individual patient. Pharmacogenetic biomarkers
require further research specific to second-line medications for the treatment of type II diabetes;
however, it is shaping up to be a promising tool implemented through the precision medicine
initiative.
Types of Precision Medicine
Often when discussing precision medicine, we jump toward pharmacogenomics and the
pharmaceutical options that can be utilized in the management and treatment of chronic diseases.
However, the literature supports precision medicine beyond that of pharmaceuticals and also
expands into lifestyle modification and machine learning (Mutie, Giordano & Franks, 2017; Kim
et al., 2018). As discussed previously, genetics can impact how individual patients respond to
specific medications, and this plays a significant role in the patient's ultimate success in treating
their type II diabetes. However, as providers, we should also be aiming at preventing type II
diabetes from occurring. It has been shown that even the successful lifestyle modifications only
delay type II diabetes by approximately three years rather than preventing it from occurring
(Mutie, Giordano & Franks, 2017). Of the research that has been completed, there have yet to be
any biomarkers identified that will have a meaningful impact on recommendations for
optimizing lifestyle modification (Mutie, Giordano & Franks, 2017). It is hopeful that with
ongoing research, these biomarkers may provide useful information in the future for
recommendations of individualized lifestyle modification for the prevention of type II diabetes.
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Along with pharmacogenomics and lifestyle modification, another application for
precision medicine is through machine learning. With type II diabetes being a multifactorial
chronic disease, it is challenging to identify recommendations that can be transferred across
populations and organizations. With the vast amount of information being gathered, our
knowledge about the human genome continues to grow. Through the utilization of artificial
intelligence in machine learning, we can enhance precision medicine by analyzing the data
available to identify critical statistics to focus on the implementation of precision medicine
within healthcare. Kim at all. (2018) created a model utilizing machine learning that would be
transferable across healthcare systems for the implementation of precision and medicine. Pulling
data from large national data sets, and multiple providers, allows healthcare models to be more
transferable, as the models are not built on a single local healthcare system data (Kim et al.,
2018). This utilization of machine learning can help precision medicine to become more
accessible to the general healthcare community.
Summary and Recommendations
1. Maturity onset diabetes in youth (MODY) and neonatal diabetes have paved the way for
the initiation of precision medicine in diabetes
2. Further stratification from type I and type II diabetes is required for further work in
precision medicine and its impact on diabetes treatment
3. Specific medications have varying individual responses based on multiple genetic
markers with mild to moderate effects.
4. Precision medicine is more than medicine but also includes lifestyle interventions and
machine learning

PRECISION MEDICINE

17

5. Further research is needed as well as cost assessment for the implementation of precision
medicine into practice
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